| Risk of hepatocellular carcinoma in patients treated with entecavir vs tenofovir for chronic hepatitis B: a Korean nationwide cohort study J Choi, HJ Kim, J Lee, S Cho, MJ Ko, YS Lim JAMA oncology 5 (1), 30-36, 2019 | 271 | 2019 |
| High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B GA Kim, YS Lim, S Han, J Choi, JH Shim, KM Kim, HC Lee, YS Lee Gut 67 (5), 945-952, 2018 | 262 | 2018 |
| Longitudinal assessment of three serum biomarkers to detect very early‐stage hepatocellular carcinoma J Choi, GA Kim, S Han, W Lee, S Chun, YS Lim Hepatology 69 (5), 1983-1994, 2019 | 165 | 2019 |
| Aspirin use and the risk of cholangiocarcinoma J Choi, HM Ghoz, T Peeraphatdit, E Baichoo, BD Addissie, WS Harmsen, ... Hepatology 64 (3), 785-796, 2016 | 122 | 2016 |
| Increasing burden of liver cancer despite extensive use of antiviral agents in a hepatitis B virus‐endemic population J Choi, S Han, N Kim, YS Lim Hepatology 66 (5), 1454-1463, 2017 | 109 | 2017 |
| Tenofovir versus entecavir on recurrence of hepatitis B virus–related hepatocellular carcinoma after surgical resection J Choi, C Jo, YS Lim Hepatology 73 (2), 661-673, 2021 | 106 | 2021 |
| High risk of clinical events in untreated HBeAg‐negative chronic hepatitis B patients with high viral load and no significant ALT elevation GH Choi, GA Kim, J Choi, S Han, YS Lim Alimentary pharmacology & therapeutics 50 (2), 215-226, 2019 | 102 | 2019 |
| Effects of tenofovir vs entecavir on risk of hepatocellular carcinoma in patients with chronic HBV infection: a systematic review and meta-analysis WM Choi, J Choi, YS Lim Clinical Gastroenterology and Hepatology 19 (2), 246-258. e9, 2021 | 94 | 2021 |
| Moderate levels of serum hepatitis B virus DNA are associated with the highest risk of hepatocellular carcinoma in chronic hepatitis B patients GA Kim, S Han, GH Choi, J Choi, YS Lim Alimentary pharmacology & therapeutics 51 (11), 1169-1179, 2020 | 64 | 2020 |
| Tenofovir disoproxil fumarate reduces hepatocellular carcinoma, decompensation and death in chronic hepatitis B patients with cirrhosis K Liu, J Choi, A Le, TCF Yip, VWS Wong, SL Chan, HLY Chan, ... Alimentary pharmacology & therapeutics 50 (9), 1037-1048, 2019 | 63 | 2019 |
| Tenofovir alafenamide for drug-resistant hepatitis B: a randomized trial for switching from tenofovir disoproxil fumarate KS Byun, J Choi, JH Kim, YS Lee, HC Lee, YJ Kim, BC Yoo, SY Kwon, ... Clinical Gastroenterology and Hepatology 20 (2), 427-437. e5, 2022 | 59 | 2022 |
| Effectiveness and safety of nivolumab in Child–Pugh b patients with hepatocellular carcinoma: a real-world cohort study WM Choi, D Lee, JH Shim, KM Kim, YS Lim, HC Lee, C Yoo, SR Park, ... Cancers 12 (7), 1968, 2020 | 49 | 2020 |
| Monotherapy with tenofovir disoproxil fumarate for multiple drug‐resistant chronic hepatitis B: 3‐year trial YS Lim, YS Lee, GY Gwak, KS Byun, YJ Kim, J Choi, J An, HC Lee, ... Hepatology 66 (3), 772-783, 2017 | 49 | 2017 |
| Risk of hepatitis B virus reactivation in patients treated with immunotherapy for anti-cancer treatment S Yoo, D Lee, JH Shim, KM Kim, YS Lim, HC Lee, C Yoo, BY Ryoo, J Choi Clinical Gastroenterology and Hepatology 20 (4), 898-907, 2022 | 46 | 2022 |
| Monotherapy with tenofovir disoproxil fumarate for adefovir-resistant vs. entecavir-resistant chronic hepatitis B: a 5-year clinical trial YS Lim, GY Gwak, J Choi, YS Lee, KS Byun, YJ Kim, BC Yoo, SY Kwon, ... Journal of Hepatology 71 (1), 35-44, 2019 | 45 | 2019 |
| Characteristics, prevention, and management of hepatitis B virus (HBV) reactivation in HBV-infected patients who require immunosuppressive therapy J Choi, YS Lim The Journal of infectious diseases 216 (suppl_8), S778-S784, 2017 | 36 | 2017 |
| Kinetics of the neutrophil‐lymphocyte ratio during PD‐1 inhibition as a prognostic factor in advanced hepatocellular carcinoma WM Choi, JY Kim, J Choi, D Lee, JH Shim, YS Lim, HC Lee, C Yoo, ... Liver International 41 (9), 2189-2199, 2021 | 35 | 2021 |
| Entecavir versus tenofovir in patients with chronic hepatitis B: enemies or partners in the prevention of hepatocellular carcinoma SW Lee, J Choi, SU Kim, YS Lim Clinical and Molecular Hepatology 27 (3), 402, 2021 | 35 | 2021 |
| Development of machine learning-based clinical decision support system for hepatocellular carcinoma GH Choi, J Yun, J Choi, D Lee, JH Shim, HC Lee, YH Chung, YS Lee, ... Scientific reports 10 (1), 14855, 2020 | 35 | 2020 |
| Regorafenib versus nivolumab after sorafenib failure: Real‐world data in patients with hepatocellular carcinoma WM Choi, J Choi, D Lee, JH Shim, YS Lim, HC Lee, YH Chung, YS Lee, ... Hepatology communications 4 (7), 1073-1086, 2020 | 35 | 2020 |
